Lee's Summit Medical Center is proud to be part of the Sarah Cannon Cancer Institute HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.
Sarah Cannon Cancer Institute at Lee's Summit Medical Center offers a comprehensive array of diagnostic services such as the most advanced minimally-invasive technology for diagnosing and treating breast lesions, as well as a range of cancer care services from screenings, cancer treatment and survivorship. The site is staffed by skilled oncology nurses certified in chemotherapy who provide a wide variety of oncology and infusion services.
Free Risk Assessments
Eating right and exercising are great steps toward leading a healthy life, but did you know your family history, age, and countless other factors can still put you at risk for health problems? Try our free risk assessments below to estimate your personal risk of developing breast, colon or rectal cancer, and identify your different types of risk factors.
For more information, contact us at (816) 282-5821 or visit hcamidwest.com. In addition to comprehensive prevention tools, diagnostics, cutting-edge therapies and surgical treatments, Sarah Cannon Cancer Institute HCA Midwest Health also offers a cancer wellness program to help support you every step of the way.
The Commission on Cancer (CoC) publishes the Cancer Programs Practice Profile Reports (CP³R) which includes two measures for colon cancer
The (CP³R) measurement helps facilities to:
- Ensure patients are treated according to recognized standards of care,
- Promote quality improvement activities, and
- Accurately compare clinical performance among CoC accredited cancer programs.
The most current results (2013 cases) for the six breast cancer measures include:
|Measure Type||Quality Measure||Us (2013)||Missouri '12||National '12|
|Surveillance||Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer.||100%||62%||63%|
|Quality Improvement||Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection||100%||90%||88%|
|Surveillance||Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes||100%||90%||85%|
|Accountability||Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.||100%||93%||91%|
|Accountability||Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer||100%||95%||91%|
|Accountability||Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer||100%||92%||88%|
Surveillance measures can be used at the community, regional, and/or national level to monitor patterns and trends of care in order to guide policymaking and resource allocation.
Quality Improvement measures are intended to be used for internal monitoring of performance within an organization or group so that analyses and subsequent remedial actions can be taken, as appropriate.
Accountability measures can be used for such purposes as public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers.